Adalimumab biosimilar (Bionovis/The Instituto Vital Brazil)

阿达木单抗生物类似药 (Bionovis/The Instituto Vital Brazil)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAdalimumab biosimilar (Bionovis/The Instituto Vital Brazil)
Drug Alias NameAdalimumab biosimilar - Bionovis/The Instituto Vital Brazil阿达木单抗生物仿制药 (Bionovis/The Instituto Vital Brazil)
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPsoriasisCrohn DiseaseColitis, Ulcerative +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Clinical)
Highest Status in ChinaN/A
Originator CompaniesBionovisThe Instituto Vital Brazil
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBionovisThe Instituto Vital Brazil
Active IndicationsN/A
Inactive IndicationsPsoriasisCrohn DiseaseColitis, Ulcerative +[6] 

Other Information

ATC CodeL04AB04
Related LinksN/A